Significance of serum carcinoembryonic antigen and CA 15-3 in . monitoring advanced breast cancer patients treated with systemic therapy: A large-scale retrospective study

Breast Cancer

Volumn 10, Issue 1, 2003, Pages 38-44

  Kurebayashi, Junichi ^a,b   Yamamoto, Yutaka ^a   Tanaka, Katsuhiro ^a,b   Kohno, Norio ^b   Kurosumi, Masafumi ^b   Moriya, Takuya ^b   Nishimura, Reiki ^b   Ogawa, Yoshinari ^b   Taguchi, Tetsuya ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Japanese Breast Cancer Society   (Japan)

Author keywords

Breast cancer; CA 15 3; CEA; Systemic therapy; Time to progression

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0041308319     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967624     Document Type: Article

References (21)

1. Bast RC Jr, Ravdin P, Hayes DF, et al: American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol 19:1865-1878, 2001. (Pubitemid 32230890)
2. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996. (Pubitemid 26340047)
3. Stearns V, Yamauchi H, Hayes DF: Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 52:239-259, 1998. (Pubitemid 29056099)
4. Narita T, Funahashi H, Satoh Y, et al: Serum and immunohistochemical studies of NCC-ST-439 in breast cancer.J Surg Onco154:5-8, 1993. (Pubitemid 23280243)
5. Iwase H, Kobayashi S, Itoh Y, et al: Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat 33:83-88, 1995.
6. Ogawa Y, Ishikawa T, Ikeda K, et al: Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 6:4069-4072, 2000.
7. Nakata B, Ogawa Y, Ishikawa T, et al: Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89:1285-1290, 2000.
8. Cheung KL, Graves CR, Robertson JF: Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26:91-102, 2000. (Pubitemid 30182241)
9. Tondini C, Hayes DF, Gelman R, et al: Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107-4112, 1988.
10. Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64:1674-1681, 1989. (Pubitemid 19251138)
11. Vizcarra E, Lluch A, Cibrian R, et al: Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 37:209-216, 1996.
12. Guadagni F, Ferroni P, Carlini S, et al: A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7:2357-2362, 2001. (Pubitemid 32751636)
13. Williams MR, Turkes A, Pearson D, et al: The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. Eur J Surg Oncol 14:417-422, 1988. (Pubitemid 18263431)
14. Williams MR, Turkes A, Pearson D, et al: An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. BrJ Cancer 61:126-132, 1990. (Pubitemid 20043558)
15. Robertson JF, Whynes DK, Dixon A, et al: Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 72:174-177, 1995.
16. Sonoo H, Kurebayashi J: Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 26:250-257, 1996. (Pubitemid 26125852)
17. Cheung KL, Pinder SE, Paish C, et al: The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer. Int J Biol Markers 15:203-209, 2000.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000. (Pubitemid 30099779)
19. Hayward JL, Carbone PP, Heusen JC, et al: Assessment of response to therapy in advanced breast cancer. BrJ Cancer 35:292-298, 1977.
20. Hayes DF, Yamauchi H, Broadwater G, et al: Cancer and Leukemia Group B: Circulating HER-2/erbB-2/cneu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-2711, 2001. (Pubitemid 32911374)
21. Berruti A, Tampellini M, Torta M, et al: Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A:2082-2084, 1994.